NCT07047066: A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
- State
- Not started
- Phase
- Phase 2
- People
- 30 planned
- Started
- 10 Jul 2025
- Primary completion
- 31 Jul 2026
- Arms
- Fluzoparib combined with Temozolomide
- Results
- None posted
- 2 Jul 2025: Trial registered